BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22627198)

  • 1. [How to deal with those low parathyroid hormone values in dialysis patients?].
    Jean G; Lafage-Proust MH; Souberbielle JC; Granjon S; Lorriaux C; Hurot JM; Mayor B; Deleaval P; Chazot C
    Nephrol Ther; 2012 Nov; 8(6):462-7. PubMed ID: 22627198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
    Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
    Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M
    Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients.
    Jean G; Souberbielle JC; Zaoui E; Lorriaux C; Hurot JM; Mayor B; Deleaval P; Mehdi M; Chazot C
    BMC Nephrol; 2016 Oct; 17(1):153. PubMed ID: 27756251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age.
    Heaf JG; Løkkegård H
    J Nephrol; 1998; 11(4):203-10. PubMed ID: 9702872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between very low PTH levels and poor survival rates in haemodialysis patients: results from the French ARNOS cohort.
    Jean G; Lataillade D; Genet L; Legrand E; Kuentz F; Moreau-Gaudry X; Fouque D;
    Nephron Clin Pract; 2011; 118(2):c211-6. PubMed ID: 21178378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation.
    Jean G; Vanel T; Terrat JC; Chazot C
    Hemodial Int; 2010 Oct; 14(4):486-91. PubMed ID: 20955282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
    Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: does it matter?
    Carsello CB; Yen TW; Wang TS
    Surgery; 2012 Oct; 152(4):575-81; discussion 581-3. PubMed ID: 23021134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
    Ghazali A; Fardellone P; Pruna A; Atik A; Achard JM; Oprisiu R; Brazier M; Remond A; Morinière P; Garabedian M; Eastwood J; Fournier A
    Kidney Int; 1999 Jun; 55(6):2169-77. PubMed ID: 10354266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four gland parathyroidectomy without reimplantation in patients with chronic renal failure.
    Saunders RN; Karoo R; Metcalfe MS; Nicholson ML
    Postgrad Med J; 2005 Apr; 81(954):255-8. PubMed ID: 15811891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
    Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
    Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.